This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Cytokinetics second generation troponin activator, reldesemtiv, is intended to treat muscle weakness by directly activating skeletal muscle. A high concentration…
molecule
2 years ago ●
2 mins read
The Janssen pan-genotype, pan-serotype dengue virus inhibitor, JNJ-A07, demonstrates broad activity against a panel of 21 clinical isolates and has a…
molecule
2 years ago ●
1 min read
The Bayer P2X3 purinoreceptor antagonist, eliapixant (BAY1817080), is intended to treat various disorders associated with hypersensitive nerve fibers, including endometriosis. The hypothesis…
molecule
2 years ago ●
1 min read
The Turning Point Therapeutics oral, brain-penetrant ALK/ROS1/TRK kinase inhibitor, repotrectinib (TPX-0005), is a macrocyclic molecule with a small size intended to limit…
molecule
2 years ago ●
1 min read
The BMS TGFβR inhibitor prodrug, “compound 10,” demonstrates antitumor efficacy comparable to the parent compound (BMS-986260) in a syngeneic model…
molecule
2 years ago ●
1 min read
The Sanofi glucosylceramide synthase (GCS) inhibitor, venglustat, is an oral, brain-penetrant clinical candidate for GBA-mutant Parkinson’s disease and other diseases where GBA-mutations are…
molecule
2 years ago ●
1 min read
Load More
